Prophylactic action of oral fluconazole against fungal infection in neutropenic patients: A meta-analysis of 16 randomized, controlled trials

Cancer

Volumn 89, Issue 7, 2000, Pages 1611-1625

  Kanda, Yoshinobu ^a,b,c   Yamamoto, Rie ^a,c   Chizuka, Aki ^a   Hamaki, Tamae ^a   Suguro, Miyuki ^a   Arai, Chiaki ^a   Matsuyama, Tomohiro ^a   Takezako, Naoki ^a   Miwa, Akiyoshi ^a   Kern, Wolfgang ^d   Kami, Masahiro ^e   Akiyama, Hideki ^f   Hirai, Hisamaru ^b   Togawa, Atsushi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e TORANOMON HOSPITAL   (Japan)

^f TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Bone marrow transplantation; Chemotherapy; Fluconazole; Fungal infection; Meta analysis; Neutropenia; Prophylaxis; Randomized controlled study

Indexed keywords

FLUCONAZOLE; PLACEBO; POLYENE;

ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; HUMAN; INFECTION PREVENTION; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; META ANALYSIS; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; FLUCONAZOLE; HUMANS; MYCOSES; NEOPLASMS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034306850     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001001)89:7<1611::AID-CNCR27>3.0.CO;2-B     Document Type: Article

References (50)

1. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia
2. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia
3. Problems in the diagnosis of invasive fungal diseases
4. Antifungal prophylaxis in patients with hematologic malignancies: A reappraisal
5. Infectious complications of bone marrow transplantation
6. Fungemia in a cancer hospital: Changing frequency, earlier onset, and results of therapy
7. The value of fungal surveillance cultures as predictors of systemic fungal infections
8. Invasive aspergillosis in acute leukemia: Correlation with nose cultures and antibiotic use
9. Failure of amphotericin B spray to prevent aspergillosis in granulocytopenic patients
10. Evaluation of aerosol amphotericin B for prophylaxis of invasive pulmonary aspergillosis in neutropenic patients - An interim analysis of a prospective, randomized trial
11. Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: What is the state of art? Ad Hoc Working Group
12. A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections
13. Treatment of Candida albicans fungemia with fluconazole
14. Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature
15. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
16. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: Results of a randomized placebo-controlled, double-blind, multicenter trial
17. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients: Bone marrow transplantation team
18. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients: The bone marrow transplantation team
19. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias
20. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - A prospective, randomized, double-blind study
21. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients: A prospective, randomized, single-center study
22. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia
23. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy
24. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies
25. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients
26. The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida spp. from surveillance cultures
27. Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole vs oral amphotericin B
28. Preventing fungal infection in neutropenic patients with acute leukemia: Fluconazole compared with oral amphotericin B
29. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies: A multicentre study group
30. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer
31. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia
32. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukemia
33. Prophylactic use of fluconazole in neutropenic cancer patients
34. Comparison of oral fluconazole and amphotericin B in the prophylaxis of fungal infection in neutropenic patients treated for acute leukemia
35. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B
36. Fluconazole vs nystatin for the prevention of fungal infection in neutropenic children receiving cytotoxic chemotherapy
37. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia
38. Methodologic guideline for systematic reviews of randomized control trials in health care from the Potsdam consultation on meta-analysis
39. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: Correlation of colonization and clinical outcome
40. Infection prevention in acute nonlymphocytic leukemia: Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis
41. Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia
42. Protective environments and prophylactic antibiotics: A prospective controlled study of theft utility in the therapy of acute leukemia
43. Meta-analysis in clinical trials
44. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness
45. Bias in the one-step method for pooling study results
46. Systemic antifungal agents. Drug interactions of clinical significance
47. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
48. Selection of Candida glabrata in pediatric bone marrow transplant recipients receiving fluconazole
49. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis